Loading
Cardiomyopathies / Non Ischemic Cardiomyopathy / Hypertrophic Cardiomyopathy · Observational Study
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active, prospective observational study enrolling up to 10,000 participants across multiple cardiomyopathy phenotypes and conditions, with planned follow-up for mortality and sudden cardiac death outcomes over up to 5 years. No results have been posted in this registry record; the study is currently recruiting and represents a data-collection initiative rather than a completed evidence base.
Observational. Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabr…; age from 18 Years. Intervention: Cardiovascular multimodality imaging, with focus on cardiac magnetic resonance (CMR) imaging. n = 10,000. 1 site: United States.
This is an active, prospective observational study enrolling up to 10,000 participants across multiple cardiomyopathy phenotypes and conditions, with planned follow-up for mortality and sudden cardiac death outcomes over up to 5 years. No results have been posted in this registry record; the study is currently recruiting and represents a data-collection initiative rather than a completed evidence base.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is an active observational registry study with no results posted; it describes planned enrollment and outcome measures only, representing early-phase data collection.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06610019). This is a study registration, not published results. Lead sponsor: Montefiore Medical Center. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 10000 participants (ESTIMATED). Conditions: Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure. Primary outcome measures: Mortality , From index CMR imaging to time of chart review, up to 5 years; Sudden Cardiac Death , From index CMR imaging to time of chart review, up to 5 years. Brief summary: Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular disease and higher propensity for cardiovascular related mortality among Black and non-Hispanic White patients. Recently, advanced cardiac imaging has become a vital tool in diagnosis and risk stratification of cardiovascular disease. Very limited data is available on the prevalence and characteristics of different cardiovascular diseases in Hispanic and African American minority groups, therefore, studying different racial and ethnic minority groups in the Bronx population is an exceptionally valuable source to determine the prevalence of cardiomyopathies among minority groups along with study survival in this population. This study aims to determine the etiology of cardiovascular disease in a diverse patient population by utilizing various cardiovascular imaging modalities, with a focus on cardiac magnetic resonance (CMR) imaging and to develop risk stratification models by applying advanced cardiovascular imaging markers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.